|drug3708||Zithromax Oral Product Wiki||1.00|
|drug760||Chloroquine diphosphate Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention and control measures, as well as supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. An array of drugs approved for other indications as well as several investigational drugs are being studied in several hundred clinical trials that are underway across the globe; however, currently there are no clinical trials available to patients in Arizona. This study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2
Description: measured by time (days) required from initiation of treatment to improvement of clinical status from mild to symptom freeMeasure: Improvement of clinical status Time: up to 28 days
Description: the time of normalization of fever as measured by daily temperature ( - ≤36.6°C or -axilla, ≤37.2 °C oral or ≤37.8°C rectal or tympanic)Measure: Time of clinical recovery of fever Time: up to 15 days
Description: the time of alleviation of cough as measured by self reported visual analog scale (VAS) cough scale. 1=no cough, 2-3=cough sometimes, 4-6=have a cough but can still do things, 7-8=persistent cough, prevents from doing things, 9-10=cough presents a great deal of discomfortMeasure: Time of clinical recovery of cough Time: up to 28 days
Description: to determine the safety of these therapies in combinationMeasure: Safety as determined by changes in QTC intervals measured by ECG Time: up to 15 days
Description: to assess the presence or absence of side effects and whether they are tolerableMeasure: Safety as determined by presence of side effects Time: up to 15 days
Description: improvement in Wisconsin Upper Respiratory Symptom Survey (WURSS-44) 0 to 7 scale, with 0 = Do not have, 1 = Very mild, 3 = Mild, 5 = Moderate, 7 = SevereMeasure: Time to improvement Time: up to 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports